Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity

News provided by

May 20, 2011, 06:45 ET

MOUNTAIN VIEW, Calif., May 20, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the upcoming European Congress on Obesity meeting to be held May 25 to May 28, 2011, at the ICEC Lutfi Kirdar Convention & Exhibition Center in Istanbul, Turkey. The details of the presentations are as follows:

Oral presentation:
Friday, May 27 – Novel Drugs Session, Presentation time 17:15-17:30 (local time)

Authors:	Stephan Rossner, MD, PhD; Craig A. Peterson, MS; Barbara Troupin, MD, MBA
Title:	CARDIOMETABOLIC RISK REDUCTION IS DIRECTLY RELATED TO MAGNITUDE OF WEIGHT LOSS WITH LOW DOSE, CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE (PHEN/TPM CR) [T5:RS4.4]

Poster presentations:

Thursday, May 26– Hot Topic Poster Session, Presentation time 13:00-15:00 (local time)

Authors:	George A. Bray, MD; Louis J. Aronne, MD; Alok K. Gupta, MD; Wesley W. Day, PhD; Barbara Troupin, MD, MBA
Title:	EFFICACY AND TOLERABILITY OF TOPIRAMATE ALONE AND IN COMBINATION WITH PHENTERMINE [HTP.025]

Friday, May 27– Poster Session, Presentation time 13:00-15:00 (local time)

Authors:	W. Timothy Garvey, MD; Craig A. Peterson, MS; Barbara Troupin, MD, MBA
Title:	WEIGHT LOSS WITH LOW-DOSE, CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE THERAPY IMPROVES GLYCAEMIC STATUS AND PREVENTS PROGRESSION TO TYPE 2 DIABETES MELLITUS [T5:P.102]

Authors:	W. Timothy Garvey, MD; Wesley W. Day, PhD, Charles H. Bowden, MD
Title:	LONG-TERM TREATMENT WITH CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE DEMONSTRATES SUSTAINED WEIGHT LOSS OVER 108 WEEKS [T5:P.103]

All posters will be displayed in the Exhibition Hall from the afternoon of May 25th until the morning of May 28th.

About QNEXA Controlled Release Capsules

QNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has completed its phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.

CONTACT:

VIVUS, Inc.	Investor Relations:	The Trout Group
Timothy E. Morris		Brian Korb
Chief Financial Officer		[email protected]
650-934-5200		646-378-2923